Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Background Foretinib is a small-molecule, oral multikinase inhibitor primarily targeting the mesenchymal epithelial transition (MET) factor receptor, and the vascular endothelial growth factor receptor 2. We conducted a phase II study to evaluate the single-agent activity and tolerability of foretin...

Descripción completa

Detalles Bibliográficos
Autores principales: Seiwert, Tanguy, Sarantopoulos, John, Kallender, Howard, McCallum, Stewart, Keer, Harold N., Blumenschein, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589657/
https://www.ncbi.nlm.nih.gov/pubmed/22918720
http://dx.doi.org/10.1007/s10637-012-9861-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589657/
https://www.ncbi.nlm.nih.gov/pubmed/22918720
http://dx.doi.org/10.1007/s10637-012-9861-3

Ejemplares similares